Arkadios Wealth Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.18M | Buy |
5,386
+2,512
| +87% | +$1.02M | 0.06% | 322 |
|
|
2025
Q1 | $1.43M | Buy |
2,874
+1,947
| +210% | +$969K | 0.05% | 362 |
|
|
2024
Q4 | $482K | Sell |
927
-346
| -27% | -$180K | 0.03% | 556 |
|
|
2024
Q3 | $787K | Buy |
1,273
+26
| +2% | +$16.1K | 0.04% | 385 |
|
|
2024
Q2 | $690K | Buy |
1,247
+239
| +24% | +$132K | 0.05% | 373 |
|
|
2024
Q1 | $586K | Buy |
1,008
+75
| +8% | +$43.6K | 0.05% | 350 |
|
|
2023
Q4 | $495K | Buy |
933
+37
| +4% | +$19.6K | 0.04% | 369 |
|
|
2023
Q3 | $454K | Buy |
896
+224
| +33% | +$113K | 0.04% | 364 |
|
|
2023
Q2 | $350K | Sell |
672
-347
| -34% | -$181K | 0.04% | 399 |
|
|
2023
Q1 | $588K | Sell |
1,019
-125
| -11% | -$72.1K | 0.07% | 277 |
|
|
2022
Q4 | $630K | Buy |
1,144
+308
| +37% | +$170K | 0.08% | 249 |
|
|
2022
Q3 | $424K | Buy |
836
+236
| +39% | +$120K | 0.06% | 300 |
|
|
2022
Q2 | $326K | Sell |
600
-170
| -22% | -$92.4K | 0.05% | 379 |
|
|
2022
Q1 | $455K | Sell |
770
-109
| -12% | -$64.4K | 0.06% | 332 |
|
|
2021
Q4 | $587K | Sell |
879
-532
| -38% | -$355K | 0.08% | 286 |
|
|
2021
Q3 | $806K | Sell |
1,411
-60
| -4% | -$34.3K | 0.12% | 199 |
|
|
2021
Q2 | $742K | Buy |
1,471
+415
| +39% | +$209K | 0.09% | 257 |
|
|
2021
Q1 | $482K | Sell |
1,056
-75
| -7% | -$34.2K | 0.08% | 256 |
|
|
2020
Q4 | $527K | Buy |
1,131
+948
| +518% | +$442K | 0.11% | 194 |
|
|
2020
Q3 | $85.9K | Sell |
183
-11
| -6% | -$5.16K | 0.04% | 315 |
|
|
2020
Q2 | $75.3K | Buy |
194
+66
| +52% | +$25.6K | 0.04% | 303 |
|
|
2020
Q1 | $36.4K | Buy |
128
+2
| +2% | +$568 | 0.02% | 385 |
|
|
2019
Q4 | $42.4K | Buy |
+126
| New | +$42.4K | 0.03% | 335 |
|